Tenofovir Alafenamide

Tenofovir Alafenamide (TAF) is a potent antiretroviral medication used in the treatment of HIV infection. It belongs to a class of drugs known as nucleotide reverse transcriptase inhibitors (NRTIs). TAF is a prodrug of tenofovir, meaning it is converted to its active form in the body. This conversion process allows for a lower dose of the medication, which in turn results in reduced renal and bone toxicity compared to its predecessor, Tenofovir Disoproxil Fumarate (TDF).
TAF is often used in combination with other antiretroviral agents to form a highly active antiretroviral therapy (HAART) regimen. HAART is a comprehensive treatment approach that aims to suppress the viral load to undetectable levels, thereby improving the quality of life and prolonging the survival of HIV-infected individuals.
In addition to its use in HIV treatment, TAF has shown promise in the prevention of HIV acquisition in uninfected individuals who are at high risk of contracting the virus. This includes individuals who are in serodiscordant relationships (where one partner is HIV-positive and the other is HIV-negative) and men who have sex with men (MSM).